Alteplase
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Alteplase: From Acute Ischemic Stroke to Posterolateral Myocardial Infarction
One-Sentence Summary
Alteplase is a recombinant tissue-type plasminogen activator (rt-PA) recognized globally as a first-line thrombolytic agent for acute ischemic stroke, pulmonary embolism, and major thromboembolic events, but it carries no registered approvals in Saudi Arabia. The TxGNN model predicts it may be effective for Posterolateral Myocardial Infarction — a high-risk STEMI subtype characterized by ST elevation in posterior chest leads (V7–V9) — with 0 clinical trials and 3 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indications registered in Saudi Arabia |
| Predicted New Indication | Posterolateral Myocardial Infarction |
| TxGNN Prediction Score | 99.79% |
| Evidence Level | L4 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Alteplase is a recombinant tissue-type plasminogen activator (rt-PA) — a serine protease that binds fibrin within a thrombus and converts plasminogen to plasmin, which in turn cleaves fibrin strands and dissolves the clot. This fibrinolytic mechanism underlies its established efficacy in acute ischemic stroke, general STEMI, and pulmonary embolism, all of which share acute thrombotic occlusion as the common pathological driver.
Posterolateral myocardial infarction is a subtype of STEMI caused by thrombotic occlusion of the left circumflex (LCx) artery. It presents with ST elevation in posterior leads V7–V9 rather than the standard precordial leads and is frequently missed on routine 12-lead ECG, leading to delayed reperfusion. Because its core pathology — coronary artery fibrin thrombus formation — is mechanistically identical to what alteplase targets in established indications, the biological rationale for its use in this subtype is strong.
A 1998 observational study by Matetzky et al. (PMID 9502627, Journal of the American College of Cardiology) directly examined this question, demonstrating that ST elevation in posterior leads identifies a distinct posterior infarction subpopulation who may derive particular benefit from thrombolytic therapy. However, no prospective randomized controlled trial has specifically evaluated alteplase in this posterior STEMI subtype, and primary PCI remains the preferred reperfusion strategy wherever infrastructure permits. The TxGNN score of 99.79% reflects a mechanistically plausible relationship, but clinical validation for this specific anatomical subtype is still needed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9502627 | 1998 | Observational | J Am Coll Cardiol | ST elevation in posterior leads (V7–V9) during acute inferior MI identifies concomitant posterior infarction; this subgroup may derive greater benefit from thrombolytic therapy than those without posterior extension |
| 21351226 | 2011 | Case Report | Catheter Cardiovasc Interv | Primary PCI of unprotected left main with intracoronary reteplase (tPA analog) facilitation in a posterolateral acute MI patient with LVEF 30% and hemodynamic compromise; procedure was successful |
| 8480981 | 1993 | Case Report | Ann Cardiol Angiol | Late fibrinolysis with tPA in posterolateral MI; a resolving cerebral embolism occurred during treatment, underscoring the risk of left intraventricular thrombus dissolution and systemic embolism during thrombolytic therapy |
Saudi Arabia Market Information
Alteplase has no registered products or marketing authorizations in Saudi Arabia. No authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Current evidence for alteplase in posterolateral myocardial infarction consists solely of two case reports and one observational study (L4 evidence level), with no dedicated prospective trials for this specific posterior STEMI subtype; while the mechanistic rationale is compelling, clinical validation is absent and the drug is not yet marketed in Saudi Arabia.
To proceed, the following is needed:
- Formal retrieval of MOA and full pharmacology data from DrugBank and the originator package insert
- Safety, contraindication, and drug interaction data from the approved prescribing information
- Assessment of real-world posterior STEMI burden and primary PCI infrastructure availability across Saudi Arabia to establish unmet clinical need
- Prospective observational cohort study or registry in posterior STEMI (V7–V9 population) specifically evaluating alteplase reperfusion outcomes vs. primary PCI
- Regulatory pathway assessment for introducing alteplase to the Saudi Arabian market, including SFDA registration requirements and cold-chain logistics for the lyophilized product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.